Opinion|Videos|May 29, 2024
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
Author(s)Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5